Brief: Transmedics Receives Full And Unconditional FDA Ide Approval For Next-Generation Ocs Heart Enhance Trial
09/02/2026 13:16
Feb 9 (Reuters) - Transmedics Group Inc TMDX.O: TRANSMEDICS RECEIVES FULL AND UNCONDITIONAL FDA IDE APPROVAL FOR NEXT-GENERATION OCS HEART ENHANCE TRIAL Source text: ID:nPn7gQKjGa Further company coverage: TMDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on TransMedics
See all newsBrief: TransMedics Appoints Fernando Araujo As Chief Financial Officer And Reiterates 2026 Financial Outlook
Transmedics Group Inc reports results for the quarter ended June 30 - Earnings Summary
TransMedics Q2 net income declines on R&D and infrastructure expenses
Brief: Transmedics Group Q2 EPS USD 0.41
TransMedics Q1 revenue edges past estimates